NEW YORK (GenomeWeb) – OpGen announced today that it has signed a supply agreement with Thermo Fisher Scientific to combine its Acuitas Rapid Test for Pathogen ID with Thermo Fisher's real-time PCR solutions.
The deal is intended to help support the commercialization of OpGen's rapid molecular products and informatics system to help combat multidrug-resistant infections, the company said. Combining genomic analysis with bioinformatics can help healthcare providers efficiently and accurately identify bacterial antibiotic susceptibility, it added.
Under the terms of the agreement, OpGen will commercialize the Acuitas pathogen test on Thermo Fisher's new mid-throughput real-time PCR system. The firm did not specify which Thermo Fisher PCR system is included in the deal.
Further terms of the agreement were not disclosed.
"This effort supports our commitment to advancing the latest in molecular testing to help hospitals and health systems rapidly and accurately streamline protocols for informed decision-making in acute care settings," OpGen Chairman and CEO Evan Jones said in a statement. "Thermo Fisher's market leading position in PCR, its global install base makes them an ideal partner for our Acuitas Rapid Test."